Valneva SE and Pfizer Inc., have reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15.   Based on these new results, Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 clinical trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in 2022, subject to regulatory approval. Clinical Trial Findings The Phase 2 trial, VLA15-221, c...